



**Date: 4 December 2017**

**Sydney, Australia**

**ASX: NOX**

**Noxopharm Limited**

ABN 50 608 966 123

**Registered Office:**

Suite 1 Level 6  
50 Queen St  
Melbourne VIC 3000  
Australia

**Operational Office:**

Suite 3, Level 4  
828 Pacific Highway  
Gordon NSW 2072  
Australia

**Board of Directors**

**Mr Peter Marks**

Chairman  
Non-Executive  
Director

**Dr Graham Kelly**

Chief Executive Officer  
Managing Director

**Dr Ian Dixon**

Non-Executive  
Director

ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

## COMPASSIONATE USE OF NOX66 IN PATIENTS

**Sydney, 4 December 2017:** Noxopharm Limited (NOX:ASX) has become aware of information circulating in the market about an abscopal anti-cancer response in a patient receiving the Company's experimental drug, NOX66, provided under the Company's Compassionate Use Scheme.

Under ASX continuance disclosure rules, the Company feels obliged to respond to that information with the following statement:

- For privacy reasons, the Company generally is unable to comment on individual cases, although in this case the patient has given permission for the Company to confirm that there has been a response from the combined use of NOX66 and a low dosage of radiotherapy, including a response in areas that were not irradiated – i.e. an abscopal response.
- Noxopharm provides NOX66 to patients under its Compassionate Use Scheme only where patients are not eligible for a clinical trial and all other treatment options have been exhausted.
- Noxopharm is not entitled to collect detailed patient data under its Compassionate Use Scheme. Further information may be released if deemed appropriate and of scientific value by the treating physicians, with the permission of the patient.
- The Company is focused on generating data in a formal clinical program known as DARRT (Direct and Abscopal Response to Radio-Therapy) which will be the basis for future submissions to regulatory bodies.

An abscopal response is a rare phenomenon observed in patients with multiple tumours who are undergoing radiotherapy. It refers to the situation where radiotherapy is being applied in a highly localised way to shrink a small number of tumours that might be causing symptoms such as pain, but where tumours well outside of the radiation field also shrink.

Until about 10 years ago, only about 8 cases of an abscopal response were reported in the medical literature. Since the introduction of immuno-oncology drugs, isolated reports of abscopal responses have appeared, particularly in patients with malignant melanoma. This has prompted speculation that the abscopal response, at least in that cancer, is associated with an immune response.

Noxopharm is developing NOX66 as a drug that sensitises cancer cells to low dosages of radiotherapy. The objective is to bring about, at the least, a greater degree of shrinkage of those tumours being exposed to radiation (Direct Radio-Sensitising effect), and, at the most, shrinkage of all tumours in the body including those tumours not irradiated (Abscopal or Bystander effect).

#### **About Noxopharm**

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to sensitise cancer cells to radiotherapy. NOX66 is the first pipeline product, with later generation drug candidates under development.

#### **Investor & Corporate Enquiries:**

Prue Kelly  
M: 0459 022 445  
E: [info@noxopharm.com](mailto:info@noxopharm.com)

#### **Company Secretary:**

David Franks  
T: +61 2 9299 9690  
E: [dfranks@fa.com.au](mailto:dfranks@fa.com.au)

[www.noxopharm.com](http://www.noxopharm.com)

#### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.